Dr. Dan Sperling As a radiologist specializing in prostate cancer diagnosis and treatment, I’m writing to share a fear I often hear from my patients. “Will this treatment affect my sex life?” This ...

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE stock now.

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

AIE is a unique photophysical phenomenon, and its distinctive luminescence properties have demonstrated significant potential ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer ...

Swirling inside every cell are millions of microscopic messages called messenger RNAs (mRNAs). The messages are the genetic ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...